Interviews

Interviews

Experts discuss practice-changing issues

Harnessing the Power of Collaboration

ASH Clinical News spoke with Richard Pazdur, MD, director of the U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence (OCE), about the...

Long-Term Impact of the ASH Scholar Award Program

The American Society of Hematology’s (ASH) longest-running award program, the ASH Scholar Award, celebrates more than 30 years of financially supporting fellows and junior...

Revisiting Maintenance of Certification: Updates from ASH and ABIM Interview with Marc S....

In 2015, the American Board of Internal Medicine (ABIM) issued a statement in response to numerous criticisms from diplomates and specialty societies, including the...
Robert Negrin

If You Build It, They Will Come: Robert Negrin Shares His Vision for Blood...

When Robert Negrin, MD, was growing up in Silver Spring, Maryland, if someone had told his parents that their son would one day become...

Bridging the Gap: How ASH Bridge Grant Recipients are Advancing Research

Biomedical researchers are operating in a tepid – lukewarm, at best – funding environment. The National Institutes of Health (NIH), a major source of...

Grassroots Lobbying Efforts Lead to a Win for SCD Patients in Tennessee: An Interview...

Sickle cell disease (SCD) is the most common, inherited red blood cell disorder in the United States – affecting 70,000 to 100,000 Americans. Although...

Improving Care Through Technology, Policy, and Philanthropy

David Blumenthal, MD, heard the call to public service at an early age. His professional career has ranged from primary-care clinical practice to government service...

The Road to the New Sickle Cell Disease Guidelines: Interview with Co-Chair George R....

On September 9, 2014, the National Heart, Lung, and Blood Institute (NHLBI) released an evidence-based expert panel report on the management of sickle cell...
Advertisement

Current Issue

July 2017, Volume 3, Issue 8

This issue features an interview with the FDA's Richard Pazdur, highlights from the 2017 ASCO Annual Meeting, a debate about minimal residual disease in myeloma, and more.